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In vivo cocktail pathway phenotyping (ICPP) is routinely used to assess the metabolic
drug–drug interaction (mDDI) potential of new drug candidates (NDC) during drug
development. However, there are a number of potential limitations to this approach and
the use of validated drug cocktails and study protocols is essential. Typically ICPP mDDI
studies assess only the impact of interactions following multiple postulated perpetrator
doses and hence the emphasis in terms of validation of these studies has been
ensuring that there are no interactions between probe substrates. Studies assessing the
comparative impact of single and multiple doses of the postulated perpetrator have the
potential to provide richer information regarding both the clinical impact and mechanism
of mDDIs. Using modafinil as a model compound, we sought to develop an optimized
ICPP mDDI study protocol to evaluate the potential magnitude and clinical relevance of
mDDIs using a physiologically based pharmacokinetic modeling approach.
Keywords: physiological based pharmacokinetic modeling, cocktail phenotyping, metabolic drug–drug
interactions, modafinil, study protocol
INTRODUCTION
In vivo cocktail pathway phenotyping (ICPP) is a relatively new approach that facilitates the
simultaneous, but independent, assessment of the activity of multiple metabolic pathways. ICPP
is ideally suited for the assessment of the magnitude of in vivo metabolic drug–drug interactions
(mDDIs) involving cytochrome P450 (CYP) enzymes (Snyder et al., 2014). Indeed, ICPP is
routinely used to assess the mDDI potential of new drug candidates (NDC) during drug
development. However, there are a number of potential limitations to this approach, such as the
capacity for interactions between probe drugs, increased risk of adverse effects caused by probe
drugs, and increased analytical complexity (Tanaka et al., 2003). As such, the use of validated drug
cocktails and study protocols is essential.
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TABLE 1 | Substrate and inhibitor parameter values used for modafinil
substrate profile.
Physiochemical properties
Molecular weight 273.4
log Po:w 1.53
pKa (monoprotic base) 8.84
B/P (SimCYP predicted) 0.887
fup 0.4 (Wong et al., 1998a)
In vivo pharmacokinetic properties
fa (Simcyp predicted) 0.99
ka (1/h; Simcyp predicted) 3.93
Qgut (L/h; Simcyp predicted) 15.56
Vss (L/kg; Simcyp predicted) 0.72
CLpo (L/h) 3.23 (Wong et al., 1998a)
In vitro inhibition parameters (Ki;µM; Robertson et al., 2000)
CYP1A2 750
CYP2C9 750
CYP2C19 7.8
CYP2D6 1,500
CYP3A4 632
In vitro induction parameters (IndC50; µM/IndMax; Robertson et al., 2000)
CYP1A2 75/1.9
CYP2C9 N/A
CYP2C19 N/A
CYP2D6 N/A
CYP3A4 10/2.5
Po:w, neutral species octanol: buffer partition coefficient; B/P, blood-to-plasma
partition ratio; fup, fraction unbound in plasma; fa, fraction available from dosage
form; ka, first-order absorption rate constant; Vss, volume of distribution at steady
state; CLpo, oral clearance; Ki, inhibition constant; IndC50, inducer concentration
that causes half maximal induction; IndMax, maximal fold induction.
Frye et al. (1997) the “Pittsburgh cocktail” was reported
as the first validated in vivo cocktail for the assessment of
CYP enzyme activities. Today, validated drug cocktails include
the “Cooperstown” (Streetman et al., 2000a,b), “Karolinska”
(Christensen et al., 2003), and “Inje” (Ryu et al., 2007)
cocktails. Each cocktail has advantages and disadvantages,
and in some cases they have been modified to expand their
capacity (Chainuvati et al., 2003; Snyder et al., 2014) or address
limitations. The four probe drugs in the Cooperstown cocktail;
caffeine (CYP1A2), omeprazole (CYP2C19), dextromethorphan
(CYP2D6), and intravenous midazolam (CYP3A), are generally
considered the core ‘probes’ of the CYP cocktail approach.
These drugs do not interact with each other and are
not associated with significant adverse effects. However, the
intravenous administration of midazolam (probe for CYP3A)
precludes the assessment of gastrointestinal CYP3A enzyme
activity. Furthermore, this cocktail does not contain a probe
drug for CYP2C9, which accounts for approximately 18%
of the CYP protein in human liver (Miners and Birkett,
1998). These limitations are partially ameliorated by using
warfarin as a probe for CYP2C9 in the “Cooperstown 5+1”
cocktail (Chainuvati et al., 2003). The Karolinska 5-drug
FIGURE 1 | Minimal physiologically based pharmacokinetic (PBPK)
model used to simulate and predict the pharmacokinetics of
modafinil. fa, fraction absorbed; ka, absorption rate constant; FG, fraction
escaping gastrointestinal metabolism; FH, fraction escaping hepatic
metabolism; CLH, hepatic clearance; CLR, renal clearance.
FIGURE 2 | Day 0, 2 and 8 protocol for the assessment of modafinil as
a perpetration of mDDIs.
cocktail uses caffeine (CYP1A2), losartan (CYP2C9), omeprazole
(CYP2C19), debrisoquine (CYP2D6), and quinine (CYP3A)
as probe drugs. However, the simultaneous administration of
the cocktail drugs causes a significant increase of metabolic
ratio of debrisoquine. Therefore, this approach requires the
separate oral intake of debrisoquine, with additional logistical
complexity. The “Inje” cocktail comprises caffeine (CYP1A2),
losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan
(CYP2D6) and oral midazolam (CYP3A). These probe drugs
do not interact with each other and are not associated with
significant adverse effects. Furthermore, the use of these drugs as
probes facilitates the assessment of the effects of mDDIs on all
major drug metabolizing CYP enzymes including both hepatic
and gastrointestinal CYP3A.
Historically ICPP based mDDI studies have only assessed the
impact of interactions following multiple (3 to 5) doses of the
postulated ‘perpetrator,’ where an interaction perpetrator is a
compound that has the potential to alter the metabolic clearance
of other drugs. As such, the emphasis in terms of validation of
these studies has been ensuring that there are no interactions
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TABLE 2 | Comparison of modafinil pharmacokinetics in age and gender matched simulations (mean and 95 % CI) and in vivo clinical studies.
Population (age range) Dose Study CMax (mg/L) tMax (h) AUC (mg/L h) t1/2 (h)
Males (22–37 y/o; Wong et al., 1999a) 200 mg Observed 4.2 1.5 57 12
Simulation 3.0 (2.8–3.1) 1.4 (1.3–1.4) 59 (55–62) 16 (14–17)
Females (19–40 y/o; Wong et al., 1999a) 200 mg Observed 5.2 1.5 61 10
Simulation 3.3 (1.3–1.4) 1.4 (1.3–1.4) 60 (57–64) 14 (13–15)
Males (20–39 y/o; Wong et al., 1999b) 200 mg QD for 7 days Observed 6.4 2.5 79 17
Simulation 4.4 (4.2–4.7) 1.3 (1.2–1.4) 77 (72–83) 17 (16 –19)
AUC, area under the plasma concentration-time curve; CMax, maximal plasma concentration; tMax, time taken to achieve maximal plasma concentration; t1/2, elimination
half-life.
FIGURE 3 | Simulated and observed plasma concentration-time
profiles defining modafinil exposure for 200 mg QD PO dosing for
7 days. Solid line represents the mean model predicted exposure profile,
broken line represents the 95% CI for the predicted exposure profile and dots
represent observed data (±SD where reported; Wong et al., 1999b).
between probe substrates. Increasingly, however, it is recognized
that the mechanism of mDDIs both in terms of inhibition
(i.e., mechanism based versus reversible) and activation (i.e.,
induction of enzyme expression versus enhanced substrate
binding) of CYP activity can have important clinical implications.
While multiple dose mDDI studies are useful in describing the
effect of steady state dosing of the postulated perpetrator on CYP
activity, they provide limited insights regarding the mechanism
of mDDIs. Studies assessing the comparative impact of single
and multiple doses of the postulated perpetrator, providing
information both on the clinical impact and mechanism of
mDDIs, have not been routinely performed and appropriate
validated dosing protocols to facilitate such studies remain to be
defined.
Modafinil, a drug able to both induce and inhibit CYP
activities in vitro, particularly CYP3A (Robertson et al., 2000),
is an ideal candidate to assess the comparative impact of single
dose versus steady state dosing on CYP activity using an
ICPP mDDI study design. We sought to develop an optimized
ICPP mDDI study protocol to evaluate the potential magnitude
and clinical relevance of mDDIs perpetrated by modafinil
using a physiologically based pharmacokinetic (PBPK) modeling
approach.
METHODS
Structural Model
Simulations were performed using the Simcyp R© Simulator
(version 15.1; Jamei et al., 2009) with a ‘minimal PBPK model’
comprising a liver compartment and a merged compartment
representing all other organs (Howgate et al., 2006; Polasek et al.,
2009; Wattanachai et al., 2011). The differential equations used
by the simulator describing enzyme kinetics and the impact of
co-variates have been described previously (Rowland Yeo et al.,
2010).
Population Model
Unless specified otherwise, simulations were performed
using the Simcyp Healthy Volunteer population profile
with virtual study cohorts comprising an equal distribution
of healthy males and females aged 21–40 years old.
Simulation data are presented as the geometric mean and
95% confidence interval (CI) for 120 estimations (10 studies of
12 individuals).
Development of Modafinil Model
Compound (Substrate and Inhibitor) Profile
The physicochemical, blood binding, absorption, distribution,
elimination, and interaction data used to construct the modafinil
compound (substrate and inhibitor) profiles are summarized in
Table 1. A schematic depicting the minimal PBPK model used to
simulate and predict the pharmacokinetics of modafinil is shown
in Figure 1. All parameters were based on published literature
values or were model predicted based on the physicochemical
characteristics of the drug. Modafinil hepatic microsomal
intrinsic clearance (CLint) was back-calculated from clinically
observed oral clearances (CLPO; Wong et al., 1998a) using
the retrograde model function in Simcyp (Yamazaki et al.,
2015). The interaction (‘inhibitor’) profile was created based
on published in vitro microsomal inhibition and hepatocyte
induction data for CYP 1A2, 2C9, 2C19, 2D6 and 3A4
(Robertson et al., 2000). The presence of endogenous fatty
acids in microsomal preparations is known to effect the
in vitro determination of kinetic parameters for multiple CYP
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FIGURE 4 | Simulated plasma concentration-time profiles for Inje cocktail probes using two different probe dosing schedules. (A) Caffeine;
(B) Dextromethorphan; (C) Losartan; (D) Midazolam; (E) Omeprazole.
enzymes including CYP 1A2, 2C9 and 2C19 (Rowland et al.,
2008; Wattanachai et al., 2012, 2015). As such, published
K i values for CYP 1A2, 2C9, and 2C19 were scaled based
on the known effects of endogenous fatty acids on these
enzymes.
Validation of Substrate Profile
The modafinil substrate profile (simulated exposure) was
validated by comparison of the pharmacokinetics parameters
maximal plasma concentration (CMax), time to maximal plasma
concentration (tMax), area under the plasma concentration
time curve (AUC) and elimination half-life (t1/2) from
simulations with data from age and gender matched
participants from three clinical studies (n = 6–12) that
were not used in the development of the modafinil compound
profile (Wong et al., 1998a, 1999b; Robertson and Hellriegel,
2003).
STEPWISE PROCEDURE
Compound Profiles
Simulations performed to assess CYP 1A2, 2D6, 3A4 and 2C19
activities used validated Simcyp substrate profiles for caffeine,
dextromethorphan, midazolam and omeprazole, respectively
(Jamei et al., 2009). Simulations performed to assess CYP2C9
activity used a losartan substrate profile based on published
parameters (Brantley et al., 2014). Probe doses were 100 mg orally
(PO) of caffeine, 25 mg PO of losartan, 20 mg PO of enteric coated
omeprazole, 30 mg PO of dextromethorphan and 1 mg PO of
midazolam.
Validation of Study Dosing Protocol
The study dosing protocol was validated using PBPK modeling
in terms of the minimal washout period between probe doses
to facilitate assessment of CYP activity under three conditions
(baseline, single modafinil dose and steady state modafinil
dosing) and the minimal number of modafinil doses to achieve
steady state. Following a series of preliminary simulations, two
dosing protocols were assessed in full; a “Day 0, 1, 7 protocol,”
where probes were dosed at 0, 24, and 168 h, with assessment of
exposure at 200 uniformly distributed sampling time points over
192 h, and a “Day 0, 2, 8 protocol,” where probes were dosed at
0, 48, and 192 h, with assessment of exposure at 200 uniformly
distributed sampling time points over 216 h (Figure 2). Residual
concentration at 0.5 h prior to the second dose, AUC and CMax
for each probe in the absence of modafinil dosing were compared
between the protocols. Trough modafinil concentrations (0.5 h
prior to the subsequent dose) were evaluated over 7 days to
determine the minimal dosing duration required to achieve
repeat trough concentrations within 5%.
Simulated Modafinil ICPP mDDI Study
The simulated impact of a single dose of modafinil (200 mg;
PO) administered 1 h prior to the second probe dose and
steady state dosing of modafinil [200 mg PO once daily (QD)
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for 7 days] on caffeine, losartan, omeprazole, dextromethorphan
and midazolam exposure was assessed using the Day 0, 2, 8
protocol. The capacity for modafinil to perpetrate mDDIs was
predicted on the basis of the simulated probe AUC ratios,
with and without modafinil (single dose or steady state). The
geometric mean of the AUC ratio for each probe was estimated
using a mixed effects model of logarithmically transformed data.
Time period was included as a fixed effect and participant as
a random effect. Back transformation was utilized to provide
a point estimate and 95% CI for the AUC ratio. Based on
an equivalence approach a lack of effect of modafinil on CYP
activity was demonstrated if the 95% CI for the estimated
AUC ratio for the probe was contained within the range
0.85 to 1.2.
ANTICIPATED (SIMULATION) RESULTS
Optimisation and Validation of ICPP
mDDI Model
Modafinil Substrate Profile
Comparison of simulated and observed pharmacokinetic
parameters reported in Table 2 demonstrate that the modafinil
substrate profile accurately estimates exposure to this drug
following a single dose (Wong et al., 1999a; Robertson
and Hellriegel, 2003) and steady state dosing (Wong et al.,
1999b). Simulated and observed (Wong et al., 1999b) plasma
concentration-time profiles for modafinil (200 mg PO QD) over
7 days are shown in Figure 3. Estimated mean modafinil trough
concentrations were 1.00, 1.30, 1.45, 1.47, 1.52, and 1.53 mg/L
on days 2, 3, 4, 5, 6, and 7, respectively. Repeatable trough
concentrations within 5% of the highest trough concentration
were obtained from day 5 onwards. Simulations confirm that
steady state exposure to modafinil is achieved within the 7 days
perpetrator dosing period recommended by the Food and Drug
Administration (FDA) for the assessment of induction and
mechanism based inhibition mDDIs (FDA, 2012).
Study Dosing Protocol
Baseline and second dose mean plasma concentration-time
profiles for each probe obtained using the Day 0, 1, 7 and
Day 0, 2, 8 protocols are shown in Figure 4. Corresponding
residual concentration, AUC and CMax values are described in
Table 3. Simulations demonstrated significant residual caffeine
and dextromethorphan concentrations prior to the second dose
using the Day 0, 1, 7 protocols of 186 and 2.3 µg/L, respectively.
Consistent with this observation, comparison of exposure (AUC
and CMax) for probes dosed on Day 0 and Day 1 in the absence
of modafinil, demonstrate that the second dose (Day 1) mean
AUC and CMax for caffeine were increased by 9.9 and 9.8 %,
respectively, while the second dose (Day 1) mean AUC and
CMax for dextromethorphan were increased by 18.1 and 17%,
respectively. Simulations performed using the Day 0, 2, 8 protocol
demonstrated that estimated second dose (Day 2) mean AUC and
CMax values for all probes were within 5% of the corresponding
first dose (Day 0) value. Mean AUC and CMax values for probes
administered 7 days after the second dose (i.e., Day 7 or 8)
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TABLE 4 | Area under the plasma-concentration time curve (mean and 95 % CI) for probes in the absence and presence of a single dose of modafinil
(200 mg PO).
Enzyme Substrate (dose) AUC (µg/L h)
Without modafinil With modafinil Ratio
CYP1A2 Caffeine (100 mg) 16,787 (14,867–18,956) 16,713 (14,806–18,865) 1.00 (0.99–1.00)
CYP2C9 Losartan (25 mg) 575 (529–624) 571 (526–620) 0.99 (0.99–1.00)
CYP2C19 Omeprazole (20 mg) 391 (341–449) 610 (537–691) 1.56 (1.52–1.59)
CYP2D6 Dextromethorphan (30 mg) 71.6 (58.8–87.2) 71.5 (58.9–86.8) 1.00 (0.99–1.00)
CYP3A4 Midazolam (1 mg) 11.4 (10.5–13.0) 10.9 (9.6–12.4) 0.96 (0.95–0.96)
TABLE 5 | Area under the plasma-concentration time curve (mean and 95% CI) for probes in the absence and presence of modafinil (200 mg PO QD)
dosed to steady state (7 days).
Enzyme Substrate (dose) AUC (µg/L h)
Without modafinil With modafinil Ratio
CYP1A2 Caffeine (100 mg) 16,556 (14710–18633) 15,941 (14166–17939) 0.96 (0.96–0.97)
CYP2C9 Losartan (25 mg) 573 (528–623) 526 (485–571) 0.92 (0.91–0.93)
CYP2C19 Omeprazole (20 mg) 391 (341–449) 455 (413–501) 1.38 (1.32–1.44)
CYP2D6 Dextromethorphan (30 mg) 70.2 (58.2–84.7) 68.5 (57.2–82.1) 0.98 (0.97–0.98)
CYP3A4 Midazolam (5 mg) 11.2 (9.9–12.8) 5.6 (4.9–6.4) 0.50 (0.47–0.53)
FIGURE 5 | Simulated plasma concentration time curve for omeprazole in the presence and absence of modafinil. (A) Single modafinil dose; (B) Steady
state modafinil dosing.
were also invariably within 5% of the first dose (Day 0) value
with residual baseline probe concentrations of 0 µg/L (not
shown).
Assessment of Modafinil as an mDDI
Perpetrator
Simulated mean probe AUC values and ratios with 95% CIs
in the presence and absence of a single dose of modafinil and
steady state dosing of modafinil are shown in Tables 4 and 5,
respectively. Following a single oral dose of modafinil, the mean
AUC omeprazole increased by 56% (391 to 610µg/L h). However,
the magnitude of this predicted mDDI was partially attenuated
following dosing of modafinil to steady state; 38% increase in
omeprazole AUC from 391 to 455 µg/L h (Figure 5). These
data indicate that modafinil may perpetrate clinically relevant
inhibitory mDDIs when co-administered with drugs primarily
metabolized by CYP2C19. The partially attenuated interaction
simulated here following dosing of modafinil to steady state
is likely due to an increase in CYP3A4 catalyzed omeprazole
metabolism (see Discussion). Dosing of modafinil to steady state
(7 days) resulted in a 50% decrease in midazolam mean AUC
(11.2 to 5.6 µg/L h; Figure 6). These data indicate that modafinil
causes clinically relevant induction of CYP3A4 with steady state
dosing. No change in midazolam AUC was observed following
a single dose of modafinil. Similarly, no significant effect of
modafinil on CYP1A2 (caffeine), CYP2C9 (losartan) or CYP2D6
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(dextromethorphan) was observed following either a single dose
or dosing to steady state (probe drug1 AUC< 5 %).
DISCUSSION
This study reports a validated dosing protocol for the
administration of Inje cocktail probes that facilitates the
assessment of the magnitude of potential mDDIs following a
single perpetrator dose and steady state perpetrator dosing.
Consistent with the estimated half-life of modafinil in healthy
volunteers (∼15 h; Robertson and Hellriegel, 2003), simulated
steady-state concentrations were obtained with 5 days of dosing.
Repeatable simulated mean trough concentrations (defined
as within 5%) were observed from Day 5 onwards. The
minimal duration of perpetrator dosing considered sufficient to
facilitate assessment of potential induction and mechanism-based
inactivation of CYP enzymes e.g., time-dependent changes in
CYP activity is 7 days (FDA, 2012). Simulations demonstrate that
this dosing duration was also sufficient to ensure steady state
modafinil concentrations.
In order to assess changes in CYP activity caused by the
administration of the postulated mDDI perpetrator (single
or steady state dosing), ICPP based mDDI studies require
administration of probes prior to perpetrator administration
to establish baseline CYP activities (Day 0). Simulations
demonstrate that when assessing the impact of a single dose of the
postulated mDDI perpetrator, repeat probe dosing on Day 1 (i.e.,
the Day 0, 1 and 7 protocol) is suitable for evaluation of CYP 2C9
(losartan), 2C19 (omeprazole) and 3A4 (midazolam) activities
since no residual probe is present and AUC and CMax values are
equivalent to the first dose. However, this protocol is not suitable
for assessment of CYP 1A2 (caffeine) or 2D6 (dextromethorphan)
activities due to the presence of significant residual probe in
the systemic circulation at the time of the second dose (24 h),
leading to an overestimation of AUC and CMax for these probes
(Table 3). Use of this protocol will bias activity assessment toward
inhibitory mDDIs involving CYP 1A2 and 2D6 increasing the
risk of either detecting an inhibitory interaction (false positive)
or failing to detect induction (false negative).
Simulations demonstrate that when assessing the single dose
effect of the postulated mDDI perpetrator, administration of
probes 48 h after the initial dose (Day 0, 2 and 8 protocol)
is suitable for evaluation of all CYP activities since essentially
no residual probe is present and AUC and CMax values are
comparable between the first and second dose (Table 3). On this
basis, the Day 0, 2 and 8 protocol was used for the assessment
of modafinil as a perpetrator of mDDIs involving CYP and is
recommended for ICPP mDDI studies performed to assess single
dose and steady state dosing effects of the a postulated mDDI
perpetrator.
The capacity of modafinil to inhibit and induce CYP
activity has been demonstrated in vitro. Classical (i.e., [I]/K i)
extrapolation of in vitro data suggests that modafinil may
induce expression of CYP 1A2 and 3A4 and inhibit CYP
2C19 and 3A4 activities in a reversible, competitive manner
(Robertson et al., 2000). On the basis of these classically
FIGURE 6 | Simulated plasma concentration time curve for midazolam
in the presence and absence of steady state modafinil dosing.
FIGURE 7 | Simulated omeprazole fraction metabolism (fm) pie charts.
(A) The absence of modafinil dosing; (B) Following dosing of modafinil to
steady state.
extrapolated in vitro data, modafinil is classified as a ‘moderate’
inducer of CYP 3A4 by the US FDA. Increasingly, however,
it is accepted that there are several limitations (such as the
appropriate selection of [I] (Rowland et al., 2006)) associated
with the use of classical extrapolation of in vitro data when
assessing mDDIs that preclude sensible assessment of the clinical
relevance of novel interactions. Indeed, the substantial benefits
of mechanistic (PBPK) extrapolation of mDDI assessments have
been extensively reported and adopted (Sheiner and Steimer,
2000; Danhof et al., 2008; Rowland Yeo et al., 2010; Rowland
et al., 2011) and this approach is recommended for the preclinical
assessment of mDDIs for regulatory review (Zhao et al., 2011;
FDA, 2012).
On the basis of the in vitro interaction profile (warfarin;
CYP2C9; Robertson et al., 2002a), or potential for concomitant
use with other vigilance (dexamphetamine, methylphenidate)
or sedative (triazolam) agents (Wong et al., 1998b; Hellriegel
et al., 2001, 2002; Robertson et al., 2002b), a limited number
of in vivo studies assessing the mDDI potential of modafinil
have been reported. Notably, these study ‘victim’ drugs, including
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warfarin, which was administered as a racemic mix or r- and s-
enantiomers (metabolised by CYP 3A4 and 2C9, respectively)
have been substrates for multiple metabolic pathways, and as
such these studies do not readily facilitate the direct assessment
of the effects of modafinil on individual CYP enzymes. Only one
in vivo interaction study has reported the capacity of modafinil to
induce drug metabolizing CYP (Moachon et al., 1996). This study
used antipyrine, a pan-CYP substrate, with 7 days of modafinil
dosing at 100 to 500 mg BD. The results of the study suggest
that modafinil may be a weak general inducer of CYP at doses
≥400 mg/day (double the recommended daily dose), but no
definitive conclusions were possible. The study design did not
facilitate assessment of effects on individual CYP enzymes or
account for concurrent inhibition of these enzymes.
In the current study, a clinically relevant increase in
omeprazole exposure was predicted following both a single
modafinil dose and dosing of modafinil to steady state. Notably,
the apparent magnitude of the inhibitory interaction was
attenuated with dosing of modafinil to steady state; omeprazole
AUC ratios following a single modafinil dose and steady
state modafinil dosing were 1.56 (1.52–1.59) and 1.38 (1.32–
1.44), respectively. While omeprazole is primarily (88%) cleared
by CYP2C19 catalyzed demethylation and hydroxylation, the
remainder of omeprazole clearance occurs via CYP3A4 catalyzed
sulfone formation. Following repeated dosing of modafinil, which
induces CYP3A4 while inhibiting CYP2C19, the inhibitory effect
on CYP2C19 is partially offset by induction of CYP3A4. The
resulting change in fraction metabolized (fm) for omeprazole is
shown in Figure 7. These data highlight both the advantages of
mechanistic extrapolation of mDDI data when assessing complex
interactions involving victim drugs that are metabolized by
multiple enzymes (Rowland Yeo et al., 2010), and the need to
consider even minor metabolic pathways when considering the
selection of probe substrates as induction of a minor metabolic
pathway can result in a significant contribution to clearance when
induced. Where multiple enzyme involvement results in the
formation of unique metabolites for each enzyme, this potential
confounder may be overcome by the consideration of an enzyme
specific metabolic ratio. Simulations also predict that steady
state dosing of modafinil may cause clinically relevant mDDIs
resulting in reduced exposure to drugs metabolized by CYP3A4.
This observation supports the current FDA classification of
modafinil as a ‘moderate inducer’ of this enzyme (FDA, 2012).
CONCLUSION
These data support consideration of the risk of clinically relevant
mDDIs when co-administered modafinil with drugs that are
primarily cleared by CYP 2C19 and 3A4 catalyzed metabolic
pathways. In particular, given the major role of CYP3A4 in the
clearance and metabolic activation of a myriad of drugs from
various therapeutic classes including the oral contraceptive pill
and orally administered non-cytotoxic anticancer drugs (e.g.,
erlotinib, pazopanib and sunitinib; Rowland et al., 2016) potential
induction of CYP3A4 by modafinil should be considered when
evaluating new indications for this drug such as the management
of chemotherapy induced fatigue and cognitive impairment in
order to avoid a potential decrease in therapeutic response for the
co-prescribed drug that may result in therapeutic failure.
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